Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: Laboratory investigation

Journal of Neurosurgery

Volumn 108, Issue 5, 2008, Pages 979-988

  Szentirmai, Oszkar ^a,b,c   Baker, Cheryl H ^a,b   Bullain, Szofia S ^a,b,c   Lin, Ning ^c   Takahashi, Masaya ^d   Folkman, Judah ^b   Mulligan, Richard C ^a,b   Carter, Bob S ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Antiangiogenesis; Endostatin; Gene therapy; Glioblastoma multiforme; Vascular endothelial growth factor

Indexed keywords

ADENOVIRUS VECTOR; CELL NUCLEUS ANTIGEN; ENDOSTATIN; GADOLINIUM PENTETATE; HYBRID PROTEIN; IMMUNOGLOBULIN G1; LUCIFERIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 FC FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SOLUBILITY; GENETIC CODE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DOMAIN; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; VIRAL GENE THERAPY; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; ENDOSTATINS; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 43249131771     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/JNS/2008/108/5/0979     Document Type: Article

References (92)

1. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, et al: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63:8890-8898, 2003
2. Bangari DS, Mittal SK: Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 6:215-226, 2006
3. Barnett FH, Scharer-Schuksz M, Wood M, Yu X, Wagner TE, Friedlander M: Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. Gene Ther 11:1283-1289, 2004
4. Belardelli F, Gresser I, Maury C, Duvillard P, Prade M, Maunoury MT: Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. III. inhibition of growth and necrosis of tumors implanted subcutaneously. Int J Cancer 31:649-653, 1983
5. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, et al: Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133-143, 2003
6. Bjerkvig R, Read TA, Vajkoczy P, Aebischer P, Pralong W, Platt S, et al: Cell therapy using encapsulated cells producing endostatin. Acta Neurochir Suppl 88:137-141, 2003
7. Black PM: Brain tumors. Part 1. N Engl J Med 324:1471-1476, 1991
8. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56:4032-4039, 1996
9. Bouck N, Stellmach V, Hsu SC: How tumors become angiogenic. Adv Cancer Res 69:135-174, 1996
10. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ: In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1:50-62, 1999
11. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926-2935, 2000
12. Burgos JS, Rosol M, Moats RA, Khankaldyyan V, Kohn DB, Nelson MD Jr, et al: Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice. Biotechniques 34:1184-1188, 2003
13. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, et al: Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 15:378-385, 2007
14. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M: Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70:4805-4810, 1996
15. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, et al: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 93:8502-8507, 1996
16. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, et al: Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther 4:956-967, 2005
17. Damert A, Machein M, Breier G, Fujita MQ, Hanahan D, Risau W, et al: Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 57:3860-3864, 1997
18. De Bouard S, Guillamo JS, Christov C, Lefevre N, Brugieres P, Gola E, et al: Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum Gene Ther 14:883-895, 2003
19. Dvorak HF, Gresser I: Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 81:497-502, 1989
20. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D: Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297-310, 2005
21. Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
22. Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70, 1995
23. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55:426-432, 2004
24. Graepler F, Verbeek B, Graeter T, Smirnow I, Kong HL, Schuppan D, et al: Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 41:879-886, 2005
25. Guerin C, Laterra J: Regulation of angiogenesis in malignant gliomas. EXS 79:47-64, 1997
26. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883-893, 2002
27. Holland EC: Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 97:6242-6244, 2000
28. Huszthy PC, Brekken C, Pedersen TB, Thorsen F, Sakariassen PO, Skaftnesmo KO, et al: Antitumor efficacy improved by local delivery of species-specific endostatin. J Neurosurg 104:118-128, 2006
29. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, et al: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5:881-887, 1999
30. Imura S, Miyake H, Izumi K, Tashiro S, Uehara H: Correlation of vascular endothelial cell proliferation with microvessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in hepatocellular carcinoma. J Med Invest 51:202-209, 2004
31. Jensen RL, Ragel BT, Whang K, Gillespie D: Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 78:233-247, 2006
32. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, et al: Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 19:35-39, 2001
33. Kamiyama H, Takano S, Tsuboi K, Matsumura A: Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131:205-213, 2005
34. Kargiotis O, Rao JS, Kyritsis AP: Mechanisms of angiogenesis in gliomas. J Neurooncol 78:281-293, 2006
35. Kirsch M, Santarius T, Black PM, Schackert G: Therapeutic antiangiogenesis for malignant brain tumors. Onkologie 24:423-430, 2001
36. Kirsch M, Schackert G, Black PM: Angiogenesis, metastasis, and endogenous inhibition. J Neurooncol 50:173-180, 2000
37. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM: Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58:4654-4659, 1998
38. Kirsch M, Weigel P, Pinzer T, Carroll RS, Black PM, Schackert HK, et al: Therapy of hematogenous melanoma brain metastases with endostatin. Clin Cancer Res 11:1259-1267, 2005
39. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, et al: Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61:7669-7674, 2001
40. Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD, et al: Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 5:25-33, 1999
41. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, et al: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624-6628, 2001
42. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, et al: Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 98:4605-4610, 2001
43. Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, et al: Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 14:779-788, 2006
44. Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M: Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399-1405, 2003
45. Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, et al: Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91:1382-1390, 1999
46. Li XP, Li CY, Li X, Ding Y, Chan LL, Yang PH, et al: Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin. Mol Cancer Ther 5:1290-1298, 2006
47. Liu H, Peng CH, Liu YB, Wu YL, Zhao ZM, Wang Y, et al: Inhibitory effect of adeno-associated virus-mediated gene transfer of human endostatin on hepatocellular carcinoma. World J Gastroenterol 11:3331-3334, 2005
48. Maizel JV Jr, White DO, Scharff MD: The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36:115-125, 1968
49. Maizel JV Jr, White DO, Scharff MD: The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology 36:126-136, 1968
50. Meneses PI, Abrey LE, Hajjar KA, Gultekin SH, Duvoisin RM, Berns KI, et al: Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clin Cancer Res 5:3689-3694, 1999
51. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 367:576-579, 1994
52. Morimoto T, Aoyagi M, Tamaki M, Yoshino Y, Hori H, Duan L, et al: Increased levels of tissue endostatin in human malignant gliomas. Clin Cancer Res 8:2933-2938, 2002
53. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22, 1999
54. Nunes FA, Furth EE, Wilson JM, Raper SE: Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 10:2515-2526, 1999
55. Oga M, Takenaga K, Sato Y, Nakajima H, Koshikawa N, Osato K, et al: Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene. Int J Oncol 23:73-79, 2003
56. Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, et al: Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 12:778-788, 2005
57. Peroulis I, Jonas N, Saleh M: Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int J Cancer 97:839-845, 2002
58. Perri SR, Nalbantoglu J, Annabi B, Koty Z, Lejeune L, François M, et al: Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res 65:8359-8365, 2005
59. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520-529, 1994
60. Plate KH, Mennel HD: Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol 47:89-94, 1995
61. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 15:339-347, 1995
62. Puduvalli VK, Sawaya R: Antiangiogenesis-therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50:189-200, 2000
63. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, et al: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1:19-31, 1995
64. Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, et al: Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res 61:6830-6837, 2001
65. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, et al: Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 19:29-34, 2001
66. Rege TA, Fears CY, Gladson CL: Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro Oncol 7:106-121, 2005
67. Rosenstein JM, Mani N, Silverman WF, Krum JM: Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci U S A 95:7086-7091, 1998
68. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 100:13513-13518, 2003
69. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393-401, 1996
70. Schmidt NO, Ziu M, Carrabba G, Giussani C, Bello L, Sun Y, et al: Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res 10:1255-1262, 2004
71. Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748, 1991
72. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al: Identification of human brain tumour initiating cells. Nature 432:396-401, 2004
73. Sipos EP, Brem H: Local anti-angiogenic brain tumor therapies. J Neurooncol 50:181-188, 2000
74. Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, et al: Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 7:2563-2572, 2001
75. Sonoda Y, Kanamori M, Deen DF, Cheng SY, Berger MS, Pieper RO: Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis. Cancer Res 63:1962-1968, 2003
76. Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C: Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 66:129-138, 2004
77. Strik HM, Schluesener HJ, Seid K, Meyermann R, Deininger MH: Localization of endostatin in rat and human gliomas. Cancer 91:1013-1019, 2001
78. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
79. Sun Y, Wang J, Liu Y, Song X, Zhang Y, Li K, et al: Results of phase III trial of EndostarTM (rh-endostatin, YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 23 (16 Suppl):7138, 2005 (Abstract)
80. Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S, et al: Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58:365-372, 2006
81. Takano S, Kamiyama H, Tsuboi K, Matsumura A: Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathol 21:69-73, 2004
82. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, et al: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56:2185-2190, 1996
83. Tanaka T, Cao Y, Folkman J, Fine HA: Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 58:3362-3369, 1998
84. Tjin Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo KM, et al: Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13:619-627, 2006
85. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9-19, 1995
86. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
87. Whitworth A: Endostatin: are we waiting for Godot? J Natl Cancer Inst 98:731-733, 2006
88. Yamanaka R, Tanaka R: Gene therapy of brain tumor with endostatin. Drugs Today (Barc) 40:931-934, 2004
89. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ: Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90:447-454, 1998
90. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93:14765-14770, 1996
91. Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, et al: Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80:837-849, 2000
92. Zhang X, Wu J, Fei Z, Gao D, Li X, Liu X, et al: Angiostatin K(1-3) gene for treatment of human gliomas: an experimental study. Chin Med J (Engl) 113:996-1001, 2000